Your browser doesn't support javascript.
loading
Effects of an intratympanic injection of dexamethasone combined with gentamicin on the expression level of serum p0 protein antibodies in patients with meniere's disease
Geng, Yang; Cao, Wenping; Xu, Huijuan; Wu, Fengfang; Feng, Tao.
  • Geng, Yang; Zibo Central Hospital. Department of Otolaryngology. Zibo. CN
  • Cao, Wenping; Zibo Central Hospital. Department of Otolaryngology. Zibo. CN
  • Xu, Huijuan; Zibo Central Hospital. Department of Otolaryngology. Zibo. CN
  • Wu, Fengfang; Quanzhou First Hospital Affiliated to Fujian Medical University. Department of Otolaryngology. Quanzhou. CN
  • Feng, Tao; Zibo Central Hospital. Department of Otolaryngology. Zibo. CN
Clinics ; 75: e1622, 2020. tab, graf
Article Dans Anglais | LILACS | ID: biblio-1142786
ABSTRACT

OBJECTIVES:

To investigate the effects of an intratympanic injection of dexamethasone combined with gentamicin on the expression level of serum P0 protein antibodies in patients with Meniere's disease (MD).

METHODS:

A total of 136 patients with MD treated in our hospital were enrolled in this study. Among them, 68 patients were treated with an intratympanic injection of dexamethasone combined with gentamicin (observation group). Another 68 patients were treated with gentamicin alone (control group).

RESULTS:

After treatment, the expression levels of IgG and IgM in the two groups significantly decreased (p<0.05); the levels in the observation group were significantly lower than those in the control group (p<0.05). The incidences of vertigo, tinnitus, and gait instability in the observation group were significantly lower than those in the control group (p<0.05). Vestibular symptom index (VSI) scores in the observation group were significantly lower than those in the control group (p<0.05). We observed no significant difference between the two groups in the number of vertigo attacks 6 months after treatment (p>0.05).

CONCLUSION:

For patients with MD, dexamethasone combined with gentamicin can reduce the incidence of vertigo, tinnitus, and gait instability, but it has no effect on the efficacy or number of vertigo attacks 6 months after treatment. Therefore, the levels of myelin P0 protein antibodies after treatment can be used as predictors of vertigo at 6 months after treatment.
Sujets)


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Protéine P0 de la myéline / Maladie de Ménière Type d'étude: Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Clinics Thème du journal: Médicament Année: 2020 Type: Article Pays d'affiliation: Chine Institution/Pays d'affiliation: Quanzhou First Hospital Affiliated to Fujian Medical University/CN / Zibo Central Hospital/CN

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Indice: LILAS (Amériques) Sujet Principal: Protéine P0 de la myéline / Maladie de Ménière Type d'étude: Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Clinics Thème du journal: Médicament Année: 2020 Type: Article Pays d'affiliation: Chine Institution/Pays d'affiliation: Quanzhou First Hospital Affiliated to Fujian Medical University/CN / Zibo Central Hospital/CN